



Voyager Therapeutics to Host Third Quarter 2016 Investor Update Call

11/01/16

CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its third quarter 2016 investor update conference call and live webcast scheduled for Thursday, November 10, 2016 at 8:30 a.m. EDT.

The live call may be accessed by dialing (877) 851-3834 for domestic callers or +1 (631) 291-4595 for international callers, and referencing conference ID number 11101029. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager's website at www.voyagetherapeutics.com. The webcast will be archived for 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagetherapeutics.com. Follow Voyager on [LinkedIn](#).

Investor Relations:

Matt Osborne
Head of Investor Relations & Corporate Communications
857-259-5353 □
mosborne@vygr.com

Media:

Katie Engleman
Pure Communications, Inc.
910-509-3977 □
Katie@purecommunicationsinc.com

Voyager Therapeutics